What Is It?

Global Biosimilars Week (GBW) is annual social media awareness campaign, first launched in 2020 by the International Generic and Biosimilar Medicines Association (IGBA).

Engagement and the number of participants continues to grow each year. Help make this year’s campaign an even bigger success! During this week-long social media campaign, we invite patients, stakeholders, health care professionals and their organizations around the world to share resources and information about biosimilar medicines using our hashtag #GlobalBiosimilarsWeek.

Together we can create a movement to advance access of biosimilars to patients around the world.

Why Participate?

Getting involved with this annual campaign can help advance your mission and grow your own brand awareness within a broader context of a global awareness and educational initiative.

Your efforts play a critical role in educating stakeholders – including patients, medical professionals, and policymakers – to make informed decisions about their care, and ultimately provide patient access to treatment options that allow them to lead healthier lives.

2024 Theme This year’s theme focuses on Advancing Access to Biosimilars.

Better access will help more people live healthier lives worldwide.

There have been great strides made in the approval, market acceptance and adoption of biosimilar biologic medicines over the past two decades, but progress has been varied around the globe.

Patients in many countries continue to lack access to these essential treatments.

Inequity can impact patients in all geographies, globally.

Stakeholders are encouraged to share their perspectives on Advancing Access to Biosimilars.

For example:

• Why does expanded access to biosimilars matter to you or your organization? What does it mean for patients? For clinicians? For drug benefit plans and health-care systems? Others?

• What are some of the current local/national/international barriers to advancing access to biosimilars? What could be a solution? Is there a call to action you can share to help encourage a solution? To whom should that call to action be targeted?

• What are some biosimilar examples or case studies of expanded access to biologic therapies that others can look to as a model to learn from and potentially adopt?

• How can regulatory convergence, regulatory reliance, streamlined clinical development and updated regulatory policies support a robust global pipeline of new biosimilars for patients?